PPARG and coronary artery disorder: Treatment with the PPARγ agonists rosiglitazone and pioglitazone has been shown to significantly decrease arterial stiffness and arterial inflammation in diabetic patients with coronary artery disease, as well as in obese glucose-tolerant patients [17, 18].